Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ – Get Free Report) and Nyxoah (NASDAQ:NYXH – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
Profitability
This table compares Health Sciences Acquisitions Co. 2 and Nyxoah’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Health Sciences Acquisitions Co. 2 | N/A | N/A | -2.38% |
| Nyxoah | -1,043.93% | -51.68% | -40.11% |
Valuation & Earnings
This table compares Health Sciences Acquisitions Co. 2 and Nyxoah”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Health Sciences Acquisitions Co. 2 | N/A | N/A | -$380,000.00 | N/A | N/A |
| Nyxoah | $4.70 million | 75.00 | -$46.77 million | ($1.87) | -5.53 |
Volatility and Risk
Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Health Sciences Acquisitions Co. 2 and Nyxoah, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Health Sciences Acquisitions Co. 2 | 0 | 0 | 0 | 0 | 0.00 |
| Nyxoah | 0 | 0 | 5 | 0 | 3.00 |
Nyxoah has a consensus target price of $17.00, suggesting a potential upside of 64.25%. Given Nyxoah’s stronger consensus rating and higher probable upside, analysts plainly believe Nyxoah is more favorable than Health Sciences Acquisitions Co. 2.
Institutional and Insider Ownership
89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Comparatively, 17.1% of Nyxoah shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Health Sciences Acquisitions Co. 2 beats Nyxoah on 6 of the 11 factors compared between the two stocks.
About Health Sciences Acquisitions Co. 2
Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Receive News & Ratings for Health Sciences Acquisitions Co. 2 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Sciences Acquisitions Co. 2 and related companies with MarketBeat.com's FREE daily email newsletter.
